BioStem grows hospital revenue again, raises 2026 revenue outlook
BioStem Technologies posted $7.6 million in third-quarter 2026 net revenue, cut its cash to $1.0 million, and raised full-year guidance to $28-29 million.
SEC filing
5 stories
BioStem Technologies posted $7.6 million in third-quarter 2026 net revenue, cut its cash to $1.0 million, and raised full-year guidance to $28-29 million.
SEC filing
The regenerative medicine company disclosed a Form D exempt securities notice as its S-1 resale registration and going concern disclosures remain pending.
SEC filing (3)
BioStem Technologies filed an S-1 covering resale of up to 12,050,000 shares tied to a new equity purchase deal with Roth Principal Investments, alongside a Form D notice of the same offering.
SEC filing (2)
The Pompano Beach regenerative medicine company can sell shares to Roth Principal Investments over time, subject to a registration statement and price conditions.
SEC filing